Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study
Background. The most frequent cause of hyperthyroidism is Graves’ disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves’ disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Thus, the ai...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2020/4748612 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565872240099328 |
|---|---|
| author | Bogusz Falkowski Ewelina Szczepanek-Parulska Nadia Sawicka-Gutaj Aleksandra Krygier Marek Ruchala |
| author_facet | Bogusz Falkowski Ewelina Szczepanek-Parulska Nadia Sawicka-Gutaj Aleksandra Krygier Marek Ruchala |
| author_sort | Bogusz Falkowski |
| collection | DOAJ |
| description | Background. The most frequent cause of hyperthyroidism is Graves’ disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves’ disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Thus, the aim of this study was to evaluate the relationship between IL-29 and Graves’ orbitopathy (GO) in euthyroid patients. Methods. Thirty-one euthyroid patients with Graves’ disease and with active GO [clinical activity score CAS≥3/7], seventeen euthyroid patients with GD but without GO, and seventy-two healthy control subjects (CS) matched for age and gender were enrolled in the study. The following parameters were evaluated in every participant: thyroid-related hormones and autoantibodies and inflammatory markers (white blood cells, hsCRP). ELISA assay was applied to measure the concentration of IL-29. Results. We found higher level of IL-29 in GO group in comparison with CS [165 (133-747) vs. 62 (62-217) pg/mL, p<0.001]. Furthermore, participants in the subgroup with GD with GO as compared with GD without GO had higher concentration of IL-29 [165 (133-747) vs. 62 (62-558) pg/mL, p=0.031]. The ROC analysis for IL-29 revealed IL-29 cut-off of 105 pg/mL (sensitivity 1.000 and specificity 0.597) as the best value significantly indicating the presence of GO in GD [area under the ROC curve (AUC): 0.739, 95% confidence interval (CI): 0.646-0.833, p<0.001]. Conclusions. The present study revealed for the first time an elevated level of IL-29 in the serum of patients with GD and GO that might suggest its involvement in the pathogenesis of GD ocular complications. |
| format | Article |
| id | doaj-art-967466ea8bce4c9d9ec830ce7caf235b |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-967466ea8bce4c9d9ec830ce7caf235b2025-02-03T01:06:17ZengWileyMediators of Inflammation0962-93511466-18612020-01-01202010.1155/2020/47486124748612Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary StudyBogusz Falkowski0Ewelina Szczepanek-Parulska1Nadia Sawicka-Gutaj2Aleksandra Krygier3Marek Ruchala4Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, PolandDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, PolandDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, PolandDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, PolandDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, PolandBackground. The most frequent cause of hyperthyroidism is Graves’ disease (GD). Orbitopathy is the most prevalent and recognizable extrathyroidal manifestation of Graves’ disease with unrevealed pathogenesis. Interleukin 29 (IL-29) is a relatively newly discovered inflammatory cytokine. Thus, the aim of this study was to evaluate the relationship between IL-29 and Graves’ orbitopathy (GO) in euthyroid patients. Methods. Thirty-one euthyroid patients with Graves’ disease and with active GO [clinical activity score CAS≥3/7], seventeen euthyroid patients with GD but without GO, and seventy-two healthy control subjects (CS) matched for age and gender were enrolled in the study. The following parameters were evaluated in every participant: thyroid-related hormones and autoantibodies and inflammatory markers (white blood cells, hsCRP). ELISA assay was applied to measure the concentration of IL-29. Results. We found higher level of IL-29 in GO group in comparison with CS [165 (133-747) vs. 62 (62-217) pg/mL, p<0.001]. Furthermore, participants in the subgroup with GD with GO as compared with GD without GO had higher concentration of IL-29 [165 (133-747) vs. 62 (62-558) pg/mL, p=0.031]. The ROC analysis for IL-29 revealed IL-29 cut-off of 105 pg/mL (sensitivity 1.000 and specificity 0.597) as the best value significantly indicating the presence of GO in GD [area under the ROC curve (AUC): 0.739, 95% confidence interval (CI): 0.646-0.833, p<0.001]. Conclusions. The present study revealed for the first time an elevated level of IL-29 in the serum of patients with GD and GO that might suggest its involvement in the pathogenesis of GD ocular complications.http://dx.doi.org/10.1155/2020/4748612 |
| spellingShingle | Bogusz Falkowski Ewelina Szczepanek-Parulska Nadia Sawicka-Gutaj Aleksandra Krygier Marek Ruchala Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study Mediators of Inflammation |
| title | Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study |
| title_full | Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study |
| title_fullStr | Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study |
| title_full_unstemmed | Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study |
| title_short | Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study |
| title_sort | evaluation of il 29 in euthyroid patients with graves orbitopathy a preliminary study |
| url | http://dx.doi.org/10.1155/2020/4748612 |
| work_keys_str_mv | AT boguszfalkowski evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT ewelinaszczepanekparulska evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT nadiasawickagutaj evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT aleksandrakrygier evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy AT marekruchala evaluationofil29ineuthyroidpatientswithgravesorbitopathyapreliminarystudy |